Allogene Therapeutics said Zachary Roberts will succeed David Chang as president and CEO on July 1. Roberts will also join the board and currently serves as EVP of R&D and CMO at the off-the-shelf cell therapy company, while Chang will remain on the board after an eight-year tenure. The leadership change comes as the platform company continues to build clinical and manufacturing momentum in allogeneic cell therapy—an area where execution, trial timelines, and scale-up often hinge on operating cadence. For investors and collaborators, the transition is a near-term governance signal that can influence program prioritization and partner discussions.